09:57 AM EST - Theralase® Technologies Inc. : Announced today that the first patient has been enrolled into its Phase II clinical study titled “Patients with Non-Muscle Invasive Bladder Cancer, who present with Carcinoma In-Situ, who are considered Bacillus Calmette Guérin Unresponsive or are intolerant to BCG Therapy” at University Health Network in Toronto. Theralase® Technologies Inc.
shares V.TLT are trading down $0.015 at $0.32.
